专业监测看板

Evaluation of K9 in Subjects With Diabetic Macular Edema (DME)

药物 / 成分：Kamuvudine-9

登记的停止原因（原文）：Low recruitment outcome

A Study to Investigate Efficacy, Safety, Tolerability, and Pharmacokinetics of JZP441 Compared With Placebo in Participants With Narcolepsy Type 1

药物 / 成分：JZP441、Matching Placebo

登记的停止原因（原文）：The study was terminated based on a business decision by the Sponsor.

Study of Growth-promoting and Metabolic Effects of Growth Hormone (rhGH)

药物 / 成分：rhGH (Norditropine SimpleXx®)、rhGH norditropine simple Xx

登记的停止原因（原文）：no more inclusions

Lenalidomide in Kaposi Disease Associated With HIV Infection

药物 / 成分：Lenalidomide

Fludarabine and Busulfan vs. Fludarabine, Busulfan and Total Body Irradiation

药物 / 成分：Fludarabine and Busulfan plus/minus Total Body Irradiation (low dose)、Fludarabine and Busulfan + Low Dose Total Body Irradiation (LD TBI)

登记的停止原因（原文）：Lack of Accrual

Check Point Inhibition After Autologous Stem Cell Transplantation in Patients at High Risk of Post Transplant Recurrence

药物 / 成分：Ipilimumab、Nivolumab

登记的停止原因（原文）：Lack of Accrual

Safety, Efficacy, PK and PD of CTAP101 (Calcifediol) ER Capsules for SHPT in HD Patients VDI

药物 / 成分：Calcifediol Oral Capsule、Placebo oral capsule

登记的停止原因（原文）：Cohort 1 completed and cohort 2 terminated prior to initiation per company decision

An Open-Label Study of Golodirsen in Non-Ambulant Patients With Duchenne Muscular Dystrophy

药物 / 成分：Golodirsen 50 MG/1 ML Intravenous Solution [VYONDYS 53]

登记的停止原因（原文）：The Sponsor has decided to focus their resources on other areas of therapy.

Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors

药物 / 成分：CPO-100

登记的停止原因（原文）：Business Decision

A Trial of SHR3680 in Prostate Cancer Patients Who Are Candidates for Radical Prostatectomy

药物 / 成分：SHR3680、Placebo

登记的停止原因（原文）：Due to the adjustment of the sponsor's development plan, after discussion with leading PI, sponsor has decided to terminate this study.

PRV-3279-2a Trial in Systemic Lupus

药物 / 成分：PRV-3279、Placebo

登记的停止原因（原文）：Termination for Strategic Reasons

Evaluation of Raltegravir Plus Maraviroc Therapy in Controlled HIV Patients Presenting With Lipohypertrophy

药物 / 成分：Raltegravir-Maraviroc

Study of TelmisartanFor the Prevention of Acute GVHD Post Allogeneic Hematopoietic Stem Cell Transplantation

药物 / 成分：Telmisartan

登记的停止原因（原文）：Lack of Accrual

Giant Cell Arteritis and Anakinra Trial

药物 / 成分：PLACEBO、ANAKINRA

登记的停止原因（原文）：experimental treatment no longer available

Stereotactic Body Radiation Therapy Followed by Surgery in Treating Patients With Stage I-IIIA Non-small Cell Lung Cancer

药物 / 成分：Laboratory Biomarker Analysis、Quality-of-Life Assessment、Stereotactic Body Radiation Therapy、Stereotactic Body Radiation Therapy

登记的停止原因（原文）：low accrual

Study of Efficacy, Safety, and Tolerability of LNA043 in Patients With Knee Osteoarthritis

药物 / 成分：LNA043、Placebo

登记的停止原因（原文）：Study early terminated due to lack of effect (did not meet primary/ secondary endpoints). This decision was not linked to safety concerns

An Extension Study to Evaluate the Long-Term Efficacy, Safety and Tolerability of Minzasolmin (UCB0599) in Study Participants With Parkinson's Disease

药物 / 成分：Minzasolmin (UCB0599)

登记的停止原因（原文）：Based on available data, the decision was made to stop development of UCB0599/minzasolmin as treatment of Parkinson's Disease.

Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma

药物 / 成分：Venetoclax、Tazemetostat

登记的停止原因（原文）：Low accrual

Trastuzumab Deruxtecan in First-line HER2-positive Locally Advanced/MBC Patients Resistant to Trastuzumab+Pertuzumab

药物 / 成分：Trastuzumab deruxtecan

登记的停止原因（原文）：The study stopped due to insufficient accrual (only two patients were included), and the sponsor has decided on its premature termination.

A Study of TAS3351 in NSCLC Patients With EGFRmt

药物 / 成分：TAS3351

登记的停止原因（原文）：Sponsor's decision, not based on safety concerns